Condition: Liver Transplantation · Sponsor: Rennes University Hospital
The success of orthotopic liver transplantation (OLT) in treatment of liver malignancy and endstage liver disease has led to an increase in the gap between patients on waiting-lists and available liver grafts. In order to compensate for this scarcity, use of liver grafts harvested from extended criteria donors (ECD) has become more and more frequent. However, these ECD grafts are known to be associated with a higher rate of primary non function (PNF) or early allograft dysfunction (EAD) because of a greater vulnerability to ischemia-reperfusion injury (IRI). During OLT, the clamping of the portal vein induces blood congestion in the splanchnic territory leading to increased gut permeability, bacterial translocation and release of endotoxin and pro-inflammatory cytokines at revascularisation, which exacerbate IRI. Realisation of a temporary porto-caval shunt (TPCS) (i.e. end to side anastomosis between the portal vein and infrahepatic vena cava) during the anhepatic phase, avoids splanchnic congestion and could therefore decrease IRI and improve liver graft function. However, TPCS remains poorly used as no randomised trial succeeds to show its benefit on liver function due to lack of power.
This description comes directly from the study's public registry record.
Michel RAYAR, MD, PhD · 02 99 28 42 65 · michel.rayar@chu-rennes.fr
Anne GANIVET · 02 99 28 25 55 · anne.ganivet@chu-rennes.fr
Always discuss trial participation with your own doctor first.
| CHU Bordeaux | Bordeaux, France | Recruiting |
| Hospices Civils Lyon | Lyon, France | Recruiting |
| CHU Nice | Nice, France | Recruiting |
| CHU Rennes | Rennes, France | Recruiting |
| CHU Toulouse | Toulouse, France | Recruiting |
| CHU Tours | Tours, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02784119